Physician profile
Catherine Keith
NPI 1760501803
$4,233.24
in general payments reported to CMS, 2019-2025
37 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,354 · 2022: $759 · 2023: $644 · 2024: $1,048 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,044.98 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $626.76 | 2021-2025 | |
| Astellas Pharma US INC | $238.59 | 2021-2024 | Veozah |
| Lilly USA, LLC | $215.61 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $210.16 | 2021-2022 | |
| Pfizer INC. | $183.15 | 2022-2025 | |
| Eisai INC. | $157.14 | 2021-2022 | |
| Axsome Therapeutics, INC. | $146.31 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $127.52 | 2021-2022 | |
| Neos Therapeutics, LP | $122.35 | 2021-2023 | Adzenys Xr-Odt |
| Amgen INC. | $108.61 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.34 | 2021-2025 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $73.61 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $66.74 | 2021 | |
| Impel Pharmaceuticals INC. | $65.16 | 2022-2023 | Trudhesa |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Keith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.